The Gustafson laboratory focuses on developing therapeutic treatment modalities for cancer with an emphasis on the pharmacology of agents and development of animal, pharmacokinetic, and mathematical model systems that better reflect the clinical progression and pathology of cancer. Current projects include mechanism of action and pharmacology of the MEK inhibitor AZD6244 in human melanoma cell lines and tumor xenografts in mouse models alone and in combination with cytotoxic chemotherapy; drug combinations that target stromal and cancer cells; and pharmacokinetic modeling to describe, simulate and predict effects.


• PK study design for drug interactions and modeling
• Physiologically-based, population and compartmental pharmacokinetics
• Analytical assays for drugs in tissue and fluids (GLP if required) including method development and validation

• 400/day or 1200/week


• HPLC: UV/Vis or fluorescence detection and LC coupled to tandem mass spectrometry
• One ABI6500 Qtrap® and two ABI3200 Qtrap® triple quadropole units
• Agilent 1200 Series LC system – UPLC/HTC-PAL
• Rotary evaporator for sample prep, and solid phase extraction

About Dr. Gustafson

Dr. Gustafson is a professor of cancer pharmacology and director of the pharmacology core. He also holds the Shipley University Chair in Comparative Oncology. His research spans an extensive and diverse scope including cancer biology, drug discovery and activity modeling across species and experimental therapeutics. Dr. Gustafson leads the Pharmacology Shared Resource of the CCSG of the University of Colorado Comprehensive Cancer Center as well as the CCTSA Pharmacology Core at the University of Colorado Medical School.

NCBI Publication Listing


Dr. Dan Gustafson
Dr. Dan Gustafson

Professor, Pharmacology & Biomedical Engineering
Shipley University Chair in Comparative Oncology

flint animal cancer center newsletter

join our community

Be among the first to learn the latest Flint Animal Cancer Center news and pet cancer treatment information.
  • This field is for validation purposes and should be left unchanged.